MDS Proteomics Strengthens International Team; Two New Vice Presidents Bring Pharmaceutical Expertise to Leading Biotechnology Company.Business Editors TORONTO--(BUSINESS WIRE)--Jan. 23, 2002 MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Proteomics, a leading proteomics-based drug discovery company, today announced the addition of two vice presidents of drug discovery, Gregg B. Morin, Ph.D. and Mark Scheideler, Ph.D., to its management team. Both executives bring fundamental pharmaceutical expertise to MDS Proteomics -- Morin from his position as director of the department of molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and biochemistry at Geron Corporation and Scheideler from his recent position as associate director and head of neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their research at GlaxoSmithKline Pharmaceuticals. Based in two separate parts of the globe, Scheideler in Odense, Denmark and Morin in Toronto, the new vice presidents will be responsible for coordinating MDS Proteomics' intensive research programs and innovative approaches to therapeutic target discovery and validation. Scheideler and Morin will lead the company's multidisciplinary teams of scientists to fuse together cell and molecular biology Cell and Molecular Biology may refer to:
or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. and bioinformatics into a revolutionary, high-throughput drug discovery paradigm. The two will expand and lead MDS Proteomics' efforts to apply its novel proteomics approaches to redefine the discovery process and accelerate the discovery and validation of new drug and antibody targets. "Mark and Gregg are experienced biopharmaceutical executives who were attracted by MDS Proteomics' mission of developing and applying novel functional proteomics approaches to fundamentally change the discovery and clinical development process," said Frank Gleeson, president and chief executive officer of MDS Proteomics. "Their broad expertise in protein biochemistry and drug discovery research, coupled with their innovation and leadership skills, will enable them to rapidly expand and further develop MDS Proteomics' capacity to help our corporate partners to develop better medicines, faster." Morin joins MDS Proteomics after six years with Geron Corporation, a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. At Geron, Morin oversaw projects and programs focusing on telomerase telomerase /telo·mer·ase/ (te-lo´mer-as) a DNA polymerase involved in the formation of telomeres and the maintenance of telomere sequences during replication. te·lom·er·ase n. biochemistry, vector biology and functional genomics. Prior to joining Geron, Morin was an assistant professor at University of California, Davis The University of California, Davis, commonly known as UC Davis, is one of the ten campuses of the University of California, and was established as the University Farm in 1905. , where he directed several post-graduate and undergraduate students in research exploring the structure and function of human telomerase. Throughout his career Morin has published more than a dozen articles in top research publications including Cell, Nature and Science. Morin earned his doctorate degree in biochemistry from University of Colorado University of Colorado may refer to:
Scheideler brings more than 10 years of international pharmaceutical experience to MDS Proteomics. Most recently, while at GlaxoSmithKline Pharmaceuticals, he developed a strategic focus for his neurobiology research group, working across the organization to identify and develop a portfolio of novel target opportunities and by acquiring and implementing technology needed in support of lead searching and optimization efforts. Previously, he worked as a principal scientist and program manager for Health Care Discovery at Novo Nordisk Healthcare in Bagsvaerd, Denmark and as research assistant professor at Albert Einstein College of Medicine
The Albert Einstein College of Medicine (AECOM) is a graduate school of Yeshiva University. It is a private medical school located in the Jack and Pearl Resnick Campus of Yeshiva University in the Morris Park , Bronx, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . Scheideler earned his doctorate degree in biochemistry from The University of Chicago in 1982 and is also widely published in key biotechnology publications. About MDS Proteomics A pioneer in the field of proteomic-enabled drug discovery, MDS Proteomics' goal is to transform the productivity of the pharmaceutical industry in discovering and developing new medicines for the treatment of disease. The company has developed exceptional capabilities in proteomics systems, technology, supercomputing, drug design, screening and biology and is uniquely positioned to build an effective bridge between gene discovery and therapeutic development. This distinctive capability is being used in collaborations with pharmaceutical and biotechnology companies as well as for the development of the company's own product pipeline. In its proteomics facilities in Europe and North America, the company focuses on drug target discovery and validation for both antibody and small molecule therapeutics. MDS Proteomics is a majority-owned subsidiary of MDS Inc. For more information on MDS Proteomics, visit the company's Web site at http://www.mdsproteomics.com About MDS Inc. MDS Inc. (NYSE NYSE See: New York Stock Exchange :MDZ MDZ Mendez MDZ Moskauer Deutsche Zeitung (Moscow German newspaper) MDZ Maritime Defense Zone MDZ Musik Der Zukunft (music label & community) MDZ Mendoza, Mendoza, Argentina - El Plumerillo ; TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : MDS) is an international health and life sciences. Its products and services include: laboratory testing, imaging agents for nuclear medicine testing, sterilization systems for medical and consumer products, research and clinical development services for planning and delivery of cancer treatment, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 10,000 highly skilled people at its global operations on four continents. Detailed information about the company is available at the MDS Web site at www.mdsintl.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion